Ignite Creation Date:
2025-12-24 @ 3:53 PM
Ignite Modification Date:
2025-12-28 @ 7:06 PM
Study NCT ID:
NCT00105092
Status:
COMPLETED
Last Update Posted:
2007-05-01
First Post:
2005-03-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-03
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2007-02
Completion Date Type:
ACTUAL
First Submit Date:
2005-03-04
First Submit QC Date:
None
Study First Post Date:
2005-03-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2007-04-27
Last Update Post Date:
2007-05-01
Last Update Post Date Type:
ESTIMATED